Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes.

about

Inhibition of HDAC6 activity in kidney diseases: a new perspective.

P2860

Q55442467-C1E31089-E702-4124-897A-8F07551FE86D

P2860

Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes.

Item

http://www.wikidata.org/entity/Q47583741

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Profile of BAFF and its recept ...... ted with pathological classes.

@en

Profile of BAFF and its recept ...... ted with pathological classes.

@nl

type

Item

label

Profile of BAFF and its recept ...... ted with pathological classes.

@en

Profile of BAFF and its recept ...... ted with pathological classes.

@nl

prefLabel

Profile of BAFF and its recept ...... ted with pathological classes.

@en

Profile of BAFF and its recept ...... ted with pathological classes.

@nl

P1476

Profile of BAFF and its recept ...... ted with pathological classes.

@en

P2093

A Sánchez

http://www.w3.org/2001/XMLSchema#string

C A Cañas

http://www.w3.org/2001/XMLSchema#string

C A Jiménez

http://www.w3.org/2001/XMLSchema#string

F E Ospina

http://www.w3.org/2001/XMLSchema#string

G J Tobón

http://www.w3.org/2001/XMLSchema#string

I Posso-Osorio

http://www.w3.org/2001/XMLSchema#string

J Naranjo-Escobar

http://www.w3.org/2001/XMLSchema#string

J P Suso

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

The many roles of chemokines and chemokine receptors in inflammation

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

Intrarenal production of B-cell survival factors in human lupus nephritis.

The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.

B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.

Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients.

Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders

P304

961203317739132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203317739132

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29087261

http://www.w3.org/2001/XMLSchema#string

Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes.

about

P2860

P2860

Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698